-
1
-
-
70450247207
-
Mucins in cancer: Function, prognosis and therapy
-
Kufe D. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 874-885
-
-
Kufe, D.1
-
2
-
-
69049089548
-
The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
-
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5323-5337
-
-
Ma, C.1
Allison, J.P.2
Ferris, A.S.3
Finn, O.J.4
Hastings, B.M.5
Hecht, T.T.6
-
3
-
-
84901396865
-
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
-
Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, et al. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene 2013;33: 3422-31.
-
(2013)
Oncogene
, vol.33
, pp. 3422-3431
-
-
Raina, D.1
Uchida, Y.2
Kharbanda, A.3
Rajabi, H.4
Panchamoorthy, G.5
Jin, C.6
-
4
-
-
84908669769
-
Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells
-
Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong K, et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20:5423-34.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5423-5434
-
-
Kharbanda, A.1
Rajabi, H.2
Jin, C.3
Tchaicha, J.4
Kikuchi, E.5
Wong, K.6
-
5
-
-
84874743726
-
MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches
-
Kufe D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013;32: 1073-81.
-
(2013)
Oncogene
, vol.32
, pp. 1073-1081
-
-
Kufe, D.1
-
6
-
-
28544448610
-
MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin
-
Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks GSK3b-mediated phosphorylation and degradation of b-catenin. Cancer Res 2005;65:10413-22.
-
(2005)
Cancer Res
, vol.65
, pp. 10413-10422
-
-
Huang, L.1
Chen, D.2
Liu, D.3
Yin, L.4
Kharbanda, S.5
Kufe, D.6
-
7
-
-
84858994452
-
MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells
-
Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi M, et al. MUC1-C oncoprotein induces TCF7L2 activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012;287: 10703-13.
-
(2012)
J Biol Chem
, vol.287
, pp. 10703-10713
-
-
Rajabi, H.1
Ahmad, R.2
Jin, C.3
Kosugi, M.4
Alam, M.5
Joshi, M.6
-
8
-
-
84898014554
-
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition
-
Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, et al. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2013;33:1680-9.
-
(2013)
Oncogene
, vol.33
, pp. 1680-1689
-
-
Rajabi, H.1
Alam, M.2
Takahashi, H.3
Kharbanda, A.4
Guha, M.5
Ahmad, R.6
-
9
-
-
84901235589
-
Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
-
Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget 2014;5:2622-34.
-
(2014)
Oncotarget
, vol.5
, pp. 2622-2634
-
-
Alam, M.1
Rajabi, H.2
Ahmad, R.3
Jin, C.4
Kufe, D.5
-
10
-
-
84910072604
-
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
-
Kharbanda A, Rajabi H, Jin C, Alam M, Wong K, Kufe D. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 2014;5:8893-905.
-
(2014)
Oncotarget
, vol.5
, pp. 8893-8905
-
-
Kharbanda, A.1
Rajabi, H.2
Jin, C.3
Alam, M.4
Wong, K.5
Kufe, D.6
-
11
-
-
68149182606
-
Functional targeting of the MUC1 oncogene in human cancers
-
Kufe D. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009;8:1201-7.
-
(2009)
Cancer Biol Ther
, vol.8
, pp. 1201-1207
-
-
Kufe, D.1
-
12
-
-
67449127094
-
Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells
-
RainaD, Ahmad R, Joshi M, Yin L,Wu Z, Kawano T, et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009;69:5133-41.
-
(2009)
Cancer Res
, vol.69
, pp. 5133-5141
-
-
Rainad Ahmad, R.1
Joshi, M.2
Yin Lwu, Z.3
Kawano, T.4
-
13
-
-
84860279784
-
Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells
-
Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol 2012;40:1643-9.
-
(2012)
Int J Oncol
, vol.40
, pp. 1643-1649
-
-
Raina, D.1
Ahmad, R.2
Rajabi, H.3
Panchamoorthy, G.4
Kharbanda, S.5
Kufe, D.6
-
14
-
-
70450268120
-
MUC1 oncoprotein is a druggable target in human prostate cancer cells
-
Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S, et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 2009;8:3056-65.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 3056-3065
-
-
Joshi, M.D.1
Ahmad, R.2
Raina, D.3
Rajabi, H.4
Bubley, G.5
Kharbanda, S.6
-
15
-
-
79955992775
-
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells
-
Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Therapeutics 2011;10:806-16.
-
(2011)
Mol Cancer Therapeutics
, vol.10
, pp. 806-816
-
-
Raina, D.1
Kosugi, M.2
Ahmad, R.3
Panchamoorthy, G.4
Rajabi, H.5
Alam, M.6
-
16
-
-
0032494119
-
Pharmacodynamic aspects of peptide administration biological response modifiers
-
Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998;33:241-52.
-
(1998)
Adv Drug Deliv Rev
, vol.33
, pp. 241-252
-
-
Talmadge, J.E.1
-
17
-
-
21144437911
-
Rational design of shepherdin, a novel anticancer agent
-
Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68.
-
(2005)
Cancer Cell
, vol.7
, pp. 457-468
-
-
Plescia, J.1
Salz, W.2
Xia, F.3
Pennati, M.4
Zaffaroni, N.5
Daidone, M.G.6
-
18
-
-
84868145117
-
Inhibition of oncogenic Wnt signaling through direct targeting of betacatenin
-
Grossmann TN, Yeh JT, Bowman BR, Chu Q, Moellering RE, Verdine GL. Inhibition of oncogenic Wnt signaling through direct targeting of betacatenin. Proc Natl Acad Sci U S A 2012;109:17942-7.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 17942-17947
-
-
Grossmann, T.N.1
Yeh, J.T.2
Bowman, B.R.3
Chu, Q.4
Moellering, R.E.5
Verdine, G.L.6
-
19
-
-
76649141217
-
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
-
Sarafraz-Yazdi E, Bowne WB, Adler V, Sookraj KA, Wu V, Shteyler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A 2010;107:1918-23.
-
(2011)
Proc Natl Acad Sci U S A
, vol.107
, pp. 1918-1923
-
-
Sarafraz-Yazdi, E.1
Bowne, W.B.2
Adler, V.3
Sookraj, K.A.4
Wu, V.5
Shteyler, V.6
-
20
-
-
84899509680
-
ASpecific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling
-
KimD, Lee IH,Kim S, Choi M, KimH, Ahn S, et al.ASpecific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res 2014;74:1-8.
-
(2014)
Cancer Res
, vol.74
, pp. 1-8
-
-
Kimd Lee Ihkim, S.1
Choi, M.2
Kim, H.3
Ahn, S.4
-
21
-
-
84897387919
-
A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
-
Xie X, Bansal N, Shaik T, Kerrigan J, Minko T, Garbuzenko O, et al. A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts. Oncotarget 2014;5:901-7.
-
(2014)
Oncotarget
, vol.5
, pp. 901-907
-
-
Xie, X.1
Bansal, N.2
Shaik, T.3
Kerrigan, J.4
Minko, T.5
Garbuzenko, O.6
-
22
-
-
84869507166
-
Finding the optimal balance: Challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems
-
Kratz F, Warnecke A. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012;164: 221-35.
-
(2012)
J Control Release
, vol.164
, pp. 221-235
-
-
Kratz, F.1
Warnecke, A.2
-
23
-
-
84868256944
-
Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors
-
Manzoor AA, Lindner LH, Landon CD, Park JY, Simnick AJ, Dreher MR, et al. Overcoming limitations in nanoparticle drug delivery: Triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012;72:5566-75.
-
(2012)
Cancer Res
, vol.72
, pp. 5566-5575
-
-
Manzoor, A.A.1
Lindner, L.H.2
Landon, C.D.3
Park, J.Y.4
Simnick, A.J.5
Dreher, M.R.6
-
24
-
-
84858652159
-
Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation
-
Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010.
-
(2012)
Chem Soc Rev
, vol.41
, pp. 2971-3010
-
-
Kamaly, N.1
Xiao, Z.2
Valencia, P.M.3
Radovic-Moreno, A.F.4
Farokhzad, O.C.5
-
25
-
-
84902188616
-
Novel polymeric nanoparticles for intracellular delivery of peptide cargos: Antitumor efficacy of the BCL-2 conversion peptide NuBCP-9
-
Kumar M, Gupta D, Singh G, Sharma S, BhattM, Prashant CK, et al. Novel polymeric nanoparticles for intracellular delivery of peptide cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res 2014;74:1-11.
-
(2014)
Cancer Res
, vol.74
, pp. 1-11
-
-
Kumar, M.1
Gupta, D.2
Singh, G.3
Sharma, S.4
Bhattm Prashant, C.K.5
-
26
-
-
67249139762
-
Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy
-
Ko YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 2009; 6:971-7.
-
(2009)
Mol Pharm
, vol.6
, pp. 971-977
-
-
Ko, Y.T.1
Falcao, C.2
Torchilin, V.P.3
-
27
-
-
70349220917
-
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing cell growth
-
Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser J, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing cell growth. J Clin Invest 2009;119:2830-42.
-
(2009)
J Clin Invest
, vol.119
, pp. 2830-2842
-
-
Soman, N.R.1
Baldwin, S.L.2
Hu, G.3
Marsh, J.N.4
Lanza, G.M.5
Heuser, J.6
-
28
-
-
58849101367
-
Polymeric tubulysin-peptide nanoparticles with potent antitumor activity
-
Schluep T, Gunawan P, Ma L, Jensen GS, Duringer J, Hinton S, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009;15:181-9.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 181-189
-
-
Schluep, T.1
Gunawan, P.2
Ma, L.3
Jensen, G.S.4
Duringer, J.5
Hinton, S.6
-
29
-
-
84855766402
-
Nanoparticle delivery of a peptide targeting EGFR signaling
-
Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release 2012;157:279-86.
-
(2012)
J Control Release
, vol.157
, pp. 279-286
-
-
Kim, S.K.1
Huang, L.2
-
30
-
-
83455238243
-
A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain
-
Panchamoorthy G, Rehan H, Kharbanda A, Ahmad R, Kufe D. A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma 2011;30:531-5.
-
(2011)
Hybridoma
, vol.30
, pp. 531-535
-
-
Panchamoorthy, G.1
Rehan, H.2
Kharbanda, A.3
Ahmad, R.4
Kufe, D.5
-
31
-
-
79954548627
-
Recent advances in PEG-PLA block copolymer nanoparticles
-
Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine 2010;5:1057-65.
-
(2011)
Int J Nanomedicine
, vol.5
, pp. 1057-1065
-
-
Xiao, R.Z.1
Zeng, Z.W.2
Zhou, G.L.3
Wang, J.J.4
Li, F.Z.5
Wang, A.M.6
-
32
-
-
2542559832
-
Phase i and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
-
Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 3708-3716
-
-
Kim, T.Y.1
Kim, D.W.2
Chung, J.Y.3
Shin, S.G.4
Kim, S.C.5
Heo, D.S.6
-
33
-
-
84873481897
-
Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells
-
Uchida Y, Raina D, Kharbanda S, Kufe D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in treatment of breast cancer cells. Cancer Biol Ther 2013;14:127-34.
-
(2013)
Cancer Biol Ther
, vol.14
, pp. 127-134
-
-
Uchida, Y.1
Raina, D.2
Kharbanda, S.3
Kufe, D.4
-
34
-
-
84880534957
-
MUC1-C oncoprotein induces tamoxifen resistance in human breast cancer
-
Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D. MUC1-C oncoprotein induces tamoxifen resistance in human breast cancer. Mol Cancer Res 2013;11:714-23.
-
(2013)
Mol Cancer Res
, vol.11
, pp. 714-723
-
-
Kharbanda, A.1
Rajabi, H.2
Jin, C.3
Raina, D.4
Kufe, D.5
-
35
-
-
84856072436
-
Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by downregulating TIGAR expression and depleting NADPH
-
Yin L, Kosugi M, Kufe D. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by downregulating TIGAR expression and depleting NADPH. Blood 2012;119:810-6.
-
(2012)
Blood
, vol.119
, pp. 810-816
-
-
Yin, L.1
Kosugi, M.2
Kufe, D.3
-
36
-
-
33745918951
-
TIGAR, a p53-inducible regulator of glycolysis and apoptosis
-
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
-
(2006)
Cell
, vol.126
, pp. 107-120
-
-
Bensaad, K.1
Tsuruta, A.2
Ma, S.3
Vidal, M.N.4
Nakano, K.5
Bartrons, R.6
-
37
-
-
55349095456
-
Cellular senescence: Molecular mechanisms, in vivo significance, and redox considerations
-
Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal 2009;11: 59-98.
-
(2009)
Antioxid Redox Signal
, vol.11
, pp. 59-98
-
-
Muller, M.1
-
39
-
-
0037948854
-
Vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
-
Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17: 1253-70.
-
(2003)
Genes Dev
, vol.17
, pp. 1253-1270
-
-
Dontu, G.1
Abdallah, W.M.2
Foley, J.M.3
Jackson, K.W.4
Clarke, M.F.5
Kawamura, M.J.6
-
40
-
-
34548569038
-
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity
-
Liao MJ, Zhang CC, Zhou B, Zimonjic DB, Mani SA, Kaba M, et al. Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res 2007; 67:8131-8.
-
(2007)
Cancer Res
, vol.67
, pp. 8131-8138
-
-
Liao, M.J.1
Zhang, C.C.2
Zhou, B.3
Zimonjic, D.B.4
Mani, S.A.5
Kaba, M.6
-
41
-
-
70349388055
-
Therapeutic peptides for cancer therapy Part i -peptide inhibitors of signal transduction cascades
-
Bidwell GL 3rd, Raucher D. Therapeutic peptides for cancer therapy. Part I -peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009;6:1033-47.
-
(2009)
Expert Opin Drug Deliv
, vol.6
, pp. 1033-1047
-
-
Bidwell, G.L.1
Raucher, D.2
-
42
-
-
70349383205
-
Therapeutic peptides for cancer therapy Part II -cell cycle inhibitory peptides and apoptosis-inducing peptides
-
Raucher D, Moktan S, Massodi I, Bidwell GL3rd. Therapeutic peptides for cancer therapy. Part II -cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009;6: 1049-64.
-
(2009)
Expert Opin Drug Deliv
, vol.6
, pp. 1049-1064
-
-
Raucher, D.1
Moktan, S.2
Massodi, I.3
Bidwell, G.L.4
-
43
-
-
84900441753
-
Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death
-
Yin L, Kufe T, Avigan D, Kufe D. Targeting the MUC1-C oncoprotein is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated multiple myeloma cell death. Blood 2014;123:2997-3006.
-
(2014)
Blood
, vol.123
, pp. 2997-3006
-
-
Yin, L.1
Kufe, T.2
Avigan, D.3
Kufe, D.4
-
44
-
-
77949849959
-
Blends of oppositely charged PEG-PPG-PEG copolymers displaying improved physical thermogelling properties
-
Lee SY, Lee Y, Chae SU, Park TG, Ahn C. Blends of oppositely charged PEG-PPG-PEG copolymers displaying improved physical thermogelling properties. Macromol Chem Phy 2010;211:692-7.
-
(2011)
Macromol Chem Phy
, vol.211
, pp. 692-697
-
-
Lee, S.Y.1
Lee, Y.2
Chae, S.U.3
Park, T.G.4
Ahn, C.5
|